Infermedica vs XUND (2026)
Infermedica and XUND supply embeddable symptom assessment and care navigation for healthcare organizations. Infermedica extends its triage engine into conversational and nurse workflows; XUND separates symptom, suspected illness and longer term health assessments into configurable modules. Infermedica's Medical Guidance Platform uses a physician curated knowledge base and probabilistic models to select questions and recommend a care level. Delivery includes APIs, embedded interfaces and branded applications. Its Nurse Triage Co-Pilot records the engine's recommendation alongside the nurse's decision, while newer conversational and voice products put different interfaces around the engine. Existing evaluations concern specific settings, and the newer voice agent has not yet been evaluated. XUND offers Symptom Check, Illness Check and Health Check through APIs, SDKs or a configurable web application. Customers can add medical content and navigation into their care network. Its pretriage model may raise urgency but cannot lower the rule engine's assessment. A claim about never missing critical cases conflicts with reported urgent case sensitivity and the user manual's warning that serious conditions can be missed. Infermedica fits organizations combining patient assessments with nurse supported triage and conversational access. XUND fits organizations selecting distinct assessment modules and regional navigation options. Both guide users toward care within defined product scopes; XUND's separate Clinical Search serves professional reference questions.
- Patient assessment and nurse supported triage should share an engine.
- Supervisors need the nurse and engine recommendations visible together.
- Conversational or voice access is part of the planned workflow.
- Several delivery interfaces are needed across a care navigation program.
- Symptom, suspected illness and longer term risk checks have distinct roles.
- Customers need configurable medical content and network navigation.
- Regional and language scope should shape module licensing.
- An escalation only pretriage restriction is a relevant design requirement.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Infermedica and XUND are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Infermedica | XUND |
|---|---|---|
| Primary category | Clinical Decision Support | Clinical Decision Support |
| Founded | Not recorded | 2018 |
| Headquarters | Wrocław, Poland | Vienna, Austria |
| Website | infermedica.com | xund.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Infermedica, based in Wrocław, Poland, builds clinical triage that takes a patient from an undifferentiated symptom to a recommended level of care. Its inference engine, which the company describes as probabilistic models built on modified Bayesian networks and machine learning methods, reasons over a physician curated Medical Knowledge Base of more than 1,800 symptoms, 900 conditions and 340 risk factors, choosing each next question from the answers so far and ending with the most probable causes and a five level care recommendation from self care to ambulance.
Source: AI Health Index, October 2026
XUND builds medical assessment and clinical search software for insurers, healthcare providers, digital health platforms, and medical information publishers. Its Symptom Check begins with a person's symptoms and suggests possible causes and next steps. Illness Check starts with a suspected condition, while Health Check uses structured lifestyle and health-history questions to estimate longer term risks.
Source: AI Health Index, October 2026
Questions buyers ask
How do Infermedica and XUND work with the EHR?
The Triage module is listed in Epic's App Orchard to add symptom checking to MyChart, and the Intake module is integrated with ProAssist, with other record systems reached through the Infermedica API. Intake sends a structured pre-visit summary and a list of possible conditions to the physician, and Conversational Triage supports pre-fill from patient records and maps findings to ICD-10 and SNOMED.
With XUND, the product also supports clinical content integrations, including Thieme's eRef assistant, and links to provider networks or booking services. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
What evidence is published for Infermedica and XUND?
In Infermedica's case, two independent evaluations stand out.
For XUND, the card also acknowledges small datasets, uneven condition representation, and differences between expert summaries and patient questionnaires. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
How much do Infermedica and XUND leave to the clinician?
With Infermedica, the pre-triage voice agent gathers symptoms before a nurse picks up and sorts callers by clinical urgency, and its launch post says it can also guide a caller to self care, a live nurse or emergency care at any hour.
In XUND's case, the current user manual expressly warns that urgent or serious conditions can be missed. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Infermedica is based in Wroclaw, Poland, and XUND in Vienna, Austria. Neither has public base license prices. Regulatory scope differs by product; XUND's Clinical Search approval remains in progress and is separate from its assessment products.